Blog
RSS FeedPosted by Michael Wonder on 13 Mar 2018
ICER requests public comment on two draft scoping documents: treatments for high-risk prostate cancer and amyloidosis
12 March 2018 - The ICER has posted two draft scoping documents outlining planned reviews of 1) three anti-androgen therapies ...
Posted by Michael Wonder on 12 Mar 2018
Regeneron and Sanofi announce plans to make Praluent (alirocumab) more accessible and affordable for patients with the greatest health risk and unmet need
10 March 2018 - For payers willing to reduce access barriers for high-risk patients, companies will offer net price within a ...
Posted by Michael Wonder on 11 Mar 2018
Institute for Clinical and Economic Review updates value-based price benchmark for alirocumab, a PCSK9 inhibitor for treatment of high cholesterol
10 March 2018 - Based on the results of the ODYSSEY Outcomes trial, ICER has calculated two updated value-based price benchmarks, ...
Posted by Michael Wonder on 11 Mar 2018
Is ICER NICEr?
21 February 2018 - Similar to NICE in the UK and the PBAC in Australia, the Institute for Clinical and Economic ...
Posted by Michael Wonder on 20 Feb 2018
Does the USA need a national health technology assessor?
19 February 2018 - In recent years, a small non-profit research organization in Boston, Massachusetts, has quietly acquired a significant ...
Posted by Michael Wonder on 16 Feb 2018
ICER to assess treatments for amyloidosis, prostate cancer in upcoming reports
16 February 2018 - Both reports will be subject of September Midwest CEPAC meeting; open Input now being accepted until 7 ...
Posted by Michael Wonder on 29 Jan 2018
Roche haemophilia drug lowers costs despite high price: ICER
27 January 2018 - A costly new Roche Holding AG drug to treat the bleeding disorder haemophilia A could significantly reduce ...
Posted by Michael Wonder on 11 Jan 2018
Institute for Clinical and Economic Review posts draft scoping document on elagolix for endometriosis
11 January 2018 - Document open to public comment until 1 February 2018. ...
Posted by Michael Wonder on 23 Dec 2017
Institute for Clinical and Economic Review's final report on VMAT2 inhibitors for tardive dyskinesia calls for manufacturer and payer action to lower prices and assure adequate access
22 December 2017 - Evidence suggests drugs offer short-term benefits but are vastly overpriced, leading to “low value” designation and triggering ...
Posted by Michael Wonder on 15 Dec 2017
Institute for Clinical and Economic Review to assess elagolix for management of endometriosis
14 December 2017 - Open input now being accepted until 8 January 2018. ...
Posted by Michael Wonder on 05 Dec 2017
Institute for Clinical and Economic Review posts draft scoping documents for two reviews: CGRP inhibitors for migraine and update to prior review of plaque psoriasis treatments
4 December 2017 - Documents open to public comment until 22 December 2017. ...
Posted by Michael Wonder on 22 Nov 2017
Institute for Clinical and Economic Review report finds evidence limited on treatments for tardive dyskinesia; discounts of up to 90% needed to align cost of drugs with benefit to patient
21 November 2017 - Report will be subject to public deliberation during New England CEPAC meeting on 5 December 2017. ...
Posted by Michael Wonder on 10 Nov 2017
Institute for Clinical and Economic Review to assess erenumab for migraine prevention; guselkumab and tildrakizumab for plaque psoriasis
9 November 2017 - Open Input now being accepted on both topics; both reviews to be subject to public deliberation at ...
Posted by Michael Wonder on 06 Nov 2017
Institute for Clinical and Economic Review final report recommends enhanced coverage of certain non-drug management options for chronic low back pain
6 November 2017 - Evidence suggests safe and effective treatments include acupuncture, cognitive behavioral therapy, mindfulness-based stress reduction, and yoga. ...
Posted by Michael Wonder on 01 Nov 2017
Institute for Clinical and Economic Review posts draft scoping document to guide review of tezacaftor and lumacaftor for cystic fibrosis
31 October 2017 - Document open to public comment until 20 November 2017. ...